| Oct 7 |
Are Investors Undervaluing Teva Pharmaceutical Industries (TEVA) Right Now?
|
| Oct 7 |
Is Teva Pharmaceutical Industries (TEVA) Stock Outpacing Its Medical Peers This Year?
|
| Oct 4 |
Teva and mAbxience partner to develop biosimilar candidate for oncology
|
| Oct 3 |
Teva, mAbxience expand strategic partnership to include additional oncology biosimilar candidate
|
| Oct 3 |
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
|
| Oct 1 |
Teva launches first U.S. generic against Novartis antidiarrheal Sandostatin LAR
|
| Oct 1 |
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
|
| Oct 1 |
Why Are Analysts Bullish On Teva Pharmaceutical Industries Limited (TEVA) Right Now?
|
| Sep 30 |
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
|
| Sep 30 |
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
|
